S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Greek authorities rescue 91 migrants from river islet on border with Turkey
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
NYSE:GSK

GSK (GSK) Competitors

$34.11
+0.31 (+0.92%)
(As of 06/2/2023 08:48 PM ET)
Compare
Today's Range
$33.88
$34.26
50-Day Range
$33.60
$38.32
52-Week Range
$28.47
$44.75
Volume
1.99 million shs
Average Volume
3.34 million shs
Market Capitalization
$69.84 billion
P/E Ratio
4.12
Dividend Yield
3.99%
Price Target
N/A

GSK vs. ZTS, REGN, VRTX, TAK, GMAB, ALNY, HZNP, BGNE, SNY, and BMY

Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), BeiGene (BGNE), Sanofi (SNY), and Bristol-Myers Squibb (BMY). These companies are all part of the "pharmaceutical preparations" industry.

GSK vs.

GSK (NYSE:GSK) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.

13.2% of GSK shares are held by institutional investors. Comparatively, 90.2% of Zoetis shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.1% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

GSK pays an annual dividend of $1.36 per share and has a dividend yield of 4.0%. Zoetis pays an annual dividend of $1.50 per share and has a dividend yield of 0.9%. GSK pays out 16.4% of its earnings in the form of a dividend. Zoetis pays out 33.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Zoetis has a consensus target price of $221.14, suggesting a potential upside of 28.66%. Given GSK's higher probable upside, analysts clearly believe GSK is more favorable than Zoetis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.09
Zoetis
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, GSK had 2 more articles in the media than Zoetis. MarketBeat recorded 8 mentions for GSK and 6 mentions for Zoetis. GSK's average media sentiment score of 0.59 beat Zoetis' score of 0.54 indicating that GSK is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
5 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GSK has a net margin of 47.85% compared to Zoetis' net margin of 25.59%. Zoetis' return on equity of 50.26% beat GSK's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK 47.85% 43.27% 8.55%
Zoetis 25.59% 50.26% 16.24%

GSK has higher revenue and earnings than Zoetis. GSK is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$36.28 billion1.93$18.50 billion$8.284.12
Zoetis$8.09 billion9.81$2.11 billion$4.4338.80

GSK has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Zoetis received 69 more outperform votes than GSK when rated by MarketBeat users. Likewise, 77.57% of users gave Zoetis an outperform vote while only 56.79% of users gave GSK an outperform vote.

CompanyUnderperformOutperform
GSKOutperform Votes
799
56.79%
Underperform Votes
608
43.21%
ZoetisOutperform Votes
868
77.57%
Underperform Votes
251
22.43%

Summary

GSK and Zoetis tied by winning 10 of the 20 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GSK vs. The Competition

MetricGSKPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$69.84B$5.85B$4.65B$14.84B
Dividend Yield3.99%2.62%2.31%3.97%
P/E Ratio4.124.7580.0518.71
Price / Sales1.93323.043,596.759.09
Price / Cash7.6520.4096.1123.58
Price / Book5.085.295.189.18
Net Income$18.50B$189.29M$117.89M$897.06M
7 Day Performance-0.38%2.98%1.98%2.54%
1 Month Performance-7.08%2.84%2.08%3.93%
1 Year Performance-20.15%19.10%12.50%-7.86%

GSK Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZTS
Zoetis
2.8425 of 5 stars
$161.00
-2.3%
$221.14
+37.4%
+1.7%$74.40B$8.09B36.3413,800
REGN
Regeneron Pharmaceuticals
2.4896 of 5 stars
$728.60
+0.5%
$850.21
+16.7%
+17.4%$79.66B$12.17B19.8011,851Insider Selling
VRTX
Vertex Pharmaceuticals
2.1317 of 5 stars
$325.30
-1.4%
$352.59
+8.4%
+23.9%$83.78B$8.93B25.904,800
TAK
Takeda Pharmaceutical
2.1892 of 5 stars
$16.08
-0.1%
$24.67
+53.4%
+16.7%$50.89B$4.03T20.8847,347
GMAB
Genmab A/S
2.3934 of 5 stars
$39.28
-3.3%
$39.15
-0.3%
+31.4%$25.92B$2.07B35.391,660
ALNY
Alnylam Pharmaceuticals
2.3894 of 5 stars
$186.46
-1.0%
$247.20
+32.6%
+47.3%$23.22B$1.04B-21.462,002Analyst Revision
HZNP
Horizon Therapeutics Public
2.3409 of 5 stars
$99.35
-0.3%
$111.42
+12.1%
+9.5%$22.71B$3.63B62.482,115
BGNE
BeiGene
2.213 of 5 stars
$228.27
-3.6%
$289.16
+26.7%
+60.2%$21.84B$1.42B-12.299,200Positive News
SNY
Sanofi
2.3998 of 5 stars
$50.45
-3.9%
$94.50
+87.3%
-4.7%$127.23B$45.31B18.0891,573Dividend Cut
Gap Down
BMY
Bristol-Myers Squibb
2.4501 of 5 stars
$63.70
-0.2%
$79.43
+24.7%
-12.7%$133.82B$46.16B18.5734,300Analyst Revision

Related Companies and Tools

This page (NYSE:GSK) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -